ZYBERNO
Stock Report
Updated Aug 30, 2026

Artiva Biotherapeutics, Inc. (ARTV)

Healthcare • NASDAQ

$11.09

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Artiva Biotherapeutics, Inc. (ARTV) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-53.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.06x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-172.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Artiva Biotherapeutics, Inc. (ARTV) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ARTV generated -$79.76M in Owner Earnings. Capital was deployed as follows: $2.32M invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:11.09
Market Cap:$437.09M

Valuation Multiples (2)

P/B Ratio:1.26x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$145.49M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (5)

ROA:-48.2%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$28.71
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:24.16x
Quick Ratio:24.16x
Cash Ratio:20.67x

Leverage Analysis (3)

Debt To Equity Ttm:0.06x
Debt-to-Equity Ratio:0.06x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:337,695,000.00
Cash And Cash Equivalents:301,454,000.00
Long Term Debt:$6.55M
Net Debt:-$291.61M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$96.15M

Bottom Line Performance (3)

-$90.82M
Income Before Tax:$83.90M
Ebitda Ttm:-93,455,000.00

Operating Expenses (5)

Operating Expenses:96,149,000.00
R And D Expense:75,864,000.00
Sga Expense:20,285,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$368.63M
Current Assets:$352.28M
Ppe Net:5,671,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:21,131,000.00
Current Liabilities:14,581,000.00
Long Term Debt:$6.55M
Short Term Debt:$3.30M

Equity & Capital (3)

Equity:$347.50M
Retained Earnings:-$379.07M
Common Stock:5,000.00

Working Capital Items (3)

Accounts Receivable:569,000.00
Inventory:0.00
Accounts Payable:9,896,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,865,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$77.86M-$80.18M

Investment Activities (2)

Investing Cash Flow:$15.32M
Capital Expenditures Ttm:2,318,000.00

Financing Activities (3)

Financing Cash Flow:-$112.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,694,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.31
-$3.31
Earnings Per Share Ttm:-$2.30

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.95

Book Value & Capital (2)

Book Value Per Share:$8.82
Cash Per Share:7.65

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$79.76M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-2.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:ARTV
Company Name:Artiva Biotherapeutics, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:39.41M
Shares Outstanding Basic:39.41M
Shares Outstanding Diluted:39.41M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 21:42:26 UTC
Data Timestamp:2026-08-18T00:32:07.101453
Scroll to Top